March 2020 FDA Recall Drug by Nostrum Laboratories Inc
D-1059-2020 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Nostrum Laboratories Inc on March 6, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in TN, MO and the recall is currently terminated.

Recall Number: D-1059-2020

Reason for Recall
CGMP Deviations: poor manufacturing practices resulted in Labeling: Incorrect or Missing Lot and/or Exp Date, product incorrectly labeled with incorrect lot and expiration date.
Initiated
03-06-2020
Reported
04-01-2020
Quantity
4722 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nostrum Laboratories Inc
Theophylline (Anhydrous) Extended-Release Tablets, 400 mg, 100-count bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC 29033-001-01.

Batch or Lot Expiration Information

Lot# Lot: THE190501, Exp 11/2022